Serum protein expression profiling for cancer detection: Validation of a SELDI-based approach for prostate cancer

Issue title: PROTEOMICS IN DIAGNOSTICS

Article type: Research Article

Authors: Grizzle, William E. | Adam, Bao-Ling | Bigbee, William L. | Conrads, Thomas P. | Carroll, Christopher | Feng, Ziding | Izbicka, Elzbieta | Jendoubi, Moncef | Johnsey, Donald | Kagan, Jacob | Leach, Robin J. | McCarthy, Diane B. | Semmes, O. John | Srivastava, Shiv | Srivastava, Sudhir | Thompson, Ian M. | Thornquist, Mark D. | Verma, Mukesh | Zhang, Zhen | Zou, Zhiqiang

Affiliations: University of Alabama at Birmingham, Birmingham, AL, USA | Eastern Virginia Medical School, Norfolk, VA, USA | University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA | SAIC-Frederick, Frederick, MD, USA | University of Texas Health Sciences Center San Antonio, San Antonio, TX, USA | Fred Hutchinson Cancer Research Center, Seattle, WA, USA | Institute of Drug Development, San Antonio Cancer Institute, San Antonio, TX, USA | Milagen, Inc., Richmond, CA, USA | National Cancer Institute, Rockville, MD, USA | Ciphergen Biosystems, Inc., Fremont, CA, USA | Uniformed Services University of Health Sciences, Rockville, MD, USA | Johns Hopkins Medical Institutions, Baltimore, MD, USA

Note: [] Corresponding author: William E. Grizzle, M.D., Ph.D., University of Alabama at Birmingham, Zeigler Research Building-Room 408, 703 South 19th Street, Birmingham, AL 35233-0007, USA. Tel.: +1 205 934 4214; Fax: +1 205 975 7128; E-mail: [email protected]

Abstract: Multiple studies have reported that analysis of serum and other bodily fluids using surface enhanced laser desorption/ionization time of flight mass spectroscopy (SELDI-TOF-MS) can identify a "fingerprint" or "signature" of spectral peaks that can separate patients with a specific disease from normal control patients. Ultimately, classification by SELDI-TOF-MS relies on spectral differences in position and amplitude of resolved peaks. Since the reproducibility of quantitation, resolution and mass accuracy of the SELDI-TOF-MS, or any high throughput mass spectrometric technique, has never been determined this method has come under some skepticism as to its clinical usefulness. This manuscript describes a detailed design of a three-phase study to validate the clinical usefulness of SELDI-TOF-MS in the identification of patients with prostatic adenocarcinoma (PCA). At the end of this validation study, the usefulness of the general SELDI-TOF-MS approach to identifying patients with PCA will be demonstrated and how it compares with PCA diagnosis by measuring prostate specific antigen.

Keywords: SELDI-TOF-MS, prostate adenocarcinoma, validation

Journal: Disease Markers, vol. 19, no. 4-5, pp. 185-195, 2003,2004